摘要
目的探讨氨磺必利治疗精神分裂症阴性症状的效果。方法采用随机数字表法将符合《中国精神障碍分类与诊断标准第3版》(CCMD-3)精神分裂症诊断标准的72例精神分裂症患者分为氨磺必利组(研究组)和利培酮组(对照组)各36例,观察8周。采用阳性与阴性症状量表(PANSS)评定疗效,副反应量表(TESS)评定不良反应。结果经8周治疗,两组PANSS总分均较治疗前低(P均<0.01)。氨磺必利组与利培酮组有效率分别为88.9%和86.1%,差异无统计学意义(P>0.05)。但氨磺必利组阴性症状评分减分与利培酮组比较,差异有统计学意义(P<0.05)。治疗结束时两组TESS评分差异无统计学意义(P>0.05)。结论氨磺必利对精神分裂症阳性症状的疗效与利培酮相当,而对精神分裂症的阴性症状的疗效优于利培酮。
Objective To study the effectiveness of the negative symptoms of schizophrenia patients treated with amisulpride. Methods 72 patients of schizophrenia wererandomly assigned to amisulpride group（36 cases） and risperidone group（36 cases）. The efficacy were assessed by Positive and Negative Syndrome Scale （PANSS） , adverse side effect were evaluated with Treatment Emergent Symptom Scale （TESS）. Results After 8 - week treatment, the scores of PANSS in both groups decreased significantly compared to the baseline（P 〈 0.01 ）. The effective rate was 88.9% and 86.1%. No significant difference was found in effect between the two groups （ P 〉 0.05 ）. But the scores of negative symptom in amisulpride group decreased significantly compared to the risperidone group, and had significant difference （ P 〈 0.05 ）. By the end of the treatment, no significant difference was found in TESS between the two groups （ P 〉 0.05 ）. Conclusion Amisulpride is as effective as risperidone for the treatment of positive symptoms of schizophrenia pa- tients,but it＇s better than that of risperidone in the treatment of the negative symptoms.
出处
《四川精神卫生》
2014年第6期505-507,共3页
Sichuan Mental Health
